Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Deffered Revenue: 2022-2025

Historic Non-Current Deffered Revenue for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $8.6 million.

  • Stoke Therapeutics' Non-Current Deffered Revenue rose 3.22% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 3.22%. This contributed to the annual value of $33.1 million for FY2023, which is 10.26% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Non-Current Deffered Revenue is $8.6 million, which was down 11.15% from $9.6 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Non-Current Deffered Revenue peaked at $49.5 million during Q1 2022, and registered a low of $8.3 million during Q3 2024.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $21.0 million (2024), whereas its average is $23.0 million.
  • Per our database at Business Quant, Stoke Therapeutics' Non-Current Deffered Revenue tumbled by 79.64% in 2024 and then increased by 3.22% in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Non-Current Deffered Revenue stood at $36.9 million in 2022, then decreased by 10.26% to $33.1 million in 2023, then slumped by 79.64% to $8.3 million in 2024, then rose by 3.22% to $8.6 million in 2025.
  • Its last three reported values are $8.6 million in Q3 2025, $9.6 million for Q2 2025, and $10.3 million during Q1 2025.